Fog City Bio

Fog City Bio is a privately held, specialized CRO founded in 2020, offering high-end immunoassay development and optimization services. It differentiates itself through direct scientist-led project ownership, access to a broad suite of cutting-edge analytical equipment, and a focus on creating robust, automation-ready protocols for tech transfer. The company operates on a fee-for-service model, catering primarily to biopharma clients in the oncology and immunology sectors who require precise protein quantification and functional assay data to advance their therapeutic programs. Its position within the MBC BioLabs incubator suggests an early-stage, asset-light operational model.

Integrated service capability across a suite of advanced analytical technologies for immunoassay development, including ultra-sensitive detection (Simoa, AlphaLISA, HTRF), multiplex profiling (Luminex, MSD), label-free kinetics (GCI, MST, SpS), live cell analysis, and advanced imaging. Focus on automation-driven, DoE-optimized protocol development for robust tech transfer.

Competes against large, full-service CROs (e.g., LabCorp, Charles River) which offer breadth but may lack agility, and numerous small boutique labs specializing in specific techniques. Differentiation is based on direct scientist access, a wide technology portfolio under one roof, and a focus on creating transferable, automation-ready protocols for early-stage research.